Physician profile
Moris A Angulo
NPI 1477573269
$72,757.58
in general payments reported to CMS, 2019-2025
22 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,086 · 2020: $8,764 · 2021: $8,665 · 2022: $34K · 2023: $11K · 2024: $510 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,002 · Travel and Lodging: $1,732 · Food and Beverage: $1,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,002.00 |
| Travel and Lodging | $1,731.91 |
| Food and Beverage | $1,677.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $57,898.15 | 2019-2024 | Sogroya |
| Ascendis Pharma Endocrinology INC | $13,349.24 | 2022-2025 | Skytrofa |
| Biomarin Pharmaceutical INC. | $457.24 | 2022-2025 | Voxzogo 1.2mg, Palynziq |
| Soleno Therapeutics, INC. | $202.14 | 2019-2025 | Vykat Xr |
| Abbvie INC. | $154.94 | 2023-2025 | Lupron Depot |
| Neurocrine Biosciences, INC. | $150.32 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $117.76 | 2023 | Bylvay |
| Sanofi-Aventis U.S. LLC | $88.47 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $59.29 | 2024-2025 | |
| Zealand Pharma US, INC. | $29.28 | 2021 | |
| Amneal Pharmaceuticals LLC | $28.52 | 2025 | Unithroid |
| Corium, LLC | $27.40 | 2024-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $26.84 | 2024 | Qelbree |
| Tolmar, INC. | $25.37 | 2024 | |
| Pfizer INC. | $24.26 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $23.11 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.32 | 2024 | Gvoke Hypopen |
| Ucb, INC. | $19.99 | 2025 | Briviact |
| Insulet Corporation | $18.66 | 2024 | Omnipod |
| Azurity Pharmaceuticals, INC. | $18.24 | 2025 | Triptodur |
| Alexion Pharmaceuticals, INC. | $17.04 | 2024 | Ultomiris |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moris Angulo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.